Skip over main navigation
  • Log in
  • Basket: (0 items)
Hepatitis Australia
Listen
  • Search
  • Instagram
  • Twitter
  • Facebook
  • YouTube
Info line  Donate
Menu
  • About us
    • Who we are
    • Our Team
    • Our Board
    • Our Members
    • Corporate documents
    • Our website
    • Contacting Us
  • Hepatitis information
    • Liver Health
    • Hepatitis A
    • Hepatitis B
    • Hepatitis C
    • Hepatitis Statistics
    • Other Languages
  • How to get help
    • COVID-19
    • Hepatitis Infoline
    • Your Rights and Responsibilities
    • For friends and family
    • Local hepatitis organisations
  • Get involved
    • Donate
    • Share your story
  • Our work
    • Hepatitis B Program
    • Hepatitis C Program
    • Policy and Advocacy
    • Our publications
    • World Hepatitis Day
    • If tatts could talk
  • News
    • Latest News
    • Media Releases
  • Workforce
    • Community
    • Professionals
    • Training Opportunities
  • Admin
    • Log in
  • Basket: (0 items)
  1. Workforce

Hepatitis Statistics

Australia has very good health surveillance systems compared to many other countries. Surveillance reports are published to inform the national response and measure progress against targets of the National Blood-borne Viruses and Sexually Transmissible Infections Strategies 2018-2022. Australia has committed to these national targets for 2022 and has signed on to World Health Organization global hepatitis elimination targets for 2030.

The following is a selection of key statistics drawn from the latest available Australian surveillance and mapping data, and where relevant cites the corresponding national targets.

Snapshot of Hepatitis B in Australia

Prevalence

  • In 2018 there was an estimated 226,566 people living with chronic hepatitis B in Australia, representing 0.90% of the population.[1]
  • In Australia it is estimated that 68.1% of those living with chronic hepatitis B have ever been diagnosed. The national target is 80% by 2022.[2]

Care and treatment

  • Only 22.1% of those with chronic hepatitis B are engaged in care (that is, regular monitoring or receiving antiviral therapy). The national target is 50% by 2022.[3]
  • Only 9.3% of people with chronic hepatitis B receiving antiviral therapy, less than half the national target of 20% by 2022.[4]

Mortality

  • In 2018 there were an estimated 435 deaths attributable to hepatitis B (the national target requires <328 in 2022).[5]

Snapshot of Hepatitis C in Australia

Prevalence:

  • At the end of 2018 an estimated 130,089 people in Australia were living with chronic hepatitis C, down from 188,951 at the start of 2016.[6]
  • There were 10,537 notifications of hepatitis C in Australia in 2017.[7]

Treatment

  • 74,704 Australians (39% of those living with hepatitis C) received antiviral treatment between March 2016 and June 2019, over halfway to the national target of 65% by 2022.[8]
  • The number of people receiving treatment for hepatitis C continued to decline from 17,648 in the four months to June 2016 down to 3,988 for the corresponding period in 2019, with between 794 and 1,101 people treated per month during January to June 2019.[9]
  • During the period March 2016 – June 2019, some 72% of people who completed treatment received follow-up (SVR) testing to confirm treatment outcomes.[10]

Morbidity and Mortality

  • During 2017-2017 there were 66 liver transplants due to chronic hepatitis C or hepatitis C‑related hepatocellular carcinoma (liver cancer).[11]
  • An estimated 583 deaths were attributable to hepatitis C during 2016-2017.[12]

Viral Hepatitis and Aboriginal and Torres Strait Islander Australians

Aboriginal and Torres Strait Islanders are disproportionately affected by hepatitis B, with considerable variation by geographic region.

  • In 2018, Aboriginal and Torres Strait Islanders were estimated to make up 7.2% (around 16,241 individuals) of the 226,566 Australians living with chronic hepatitis B.[13]
  • Indigenous Australians are much more likely to be affected by hepatitis B if they are living in remote (5.3% affected) and very remote (5.5% affected) regions compared with major cities (where 1.1% of Aboriginal and Torres Strait Islanders are affected).[14]
  • For all populations in 2018, engagement in care (regular monitoring or antiviral treatment) and treatment uptake for people living with hepatitis B was highest in major cities (24.4% and 10.5% respectively) and lowest in remote regions (14.4% and 2.3%).[15]
  • In 2017 childhood hepatitis B vaccination coverage for Aboriginal and Torres Strait Islanders was 93% at 12 months and 97.5% at 24 months of age (compared with non-Indigenous Australians at 94.6% and 96.4% respectively).[16]
  • Highlighting the importance of vaccination coverage, data suggest hepatitis B prevalence is 80% lower in Aboriginal and Torres Strait Islander mothers born after 1988 (when childhood vaccination was introduced), compared with mothers born before 1988.[17]

Aboriginal and Torres Strait Islanders are also disproportionately affected by hepatitis C, with considerable variation by geographic region.

  • Aboriginal and Torres Strait Islanders make up 3% of the Australian population, but at least 11% of newly reported cases of hepatitis C each year.[18]
  • They report higher rates of risk factors for hepatitis C, including receptive sharing of injecting equipment and are over-represented in corrections settings.[19]
  • There is no current estimate of Indigenous hepatitis C population prevalence, although 2007 modelling estimated there were between 13,000 and 22,000 Aboriginal and Torres Strait Islanders living with hepatitis C.[20]
  • Infections in people aged under 25 years (which help estimate the number of recent infections across all ages) in 2017 were six times higher among Aboriginal and Torres Strait Islanders (76.7 per 100,000 people) than for non-Indigenous people (12.2 per 100,000).[21]
  • Whilst most people living with hepatitis C live in metropolitan areas, those living in rural and remote areas are more likely to have hepatitis C.[22]
  • Access to treatment is approximately twice as high in urban and regional areas as it is in remote regions of Australia.[23]
References

[1] ASHM. Viral Hepatitis Mapping Project: National Report 2018-19.

[2] Ibid.

[3] Ibid.

[4] Ibid.

[5] Doherty Institute. National Surveillance for Hepatitis B Indicators: Measuring the progress towards the targets of the National Hepatitis B Strategy – Annual Report 2018.

[6] ASHM. Viral Hepatitis Mapping Project: National Report 2018-19.

[7] Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia: Annual surveillance report 2018.

[8] ASHM. Viral Hepatitis Mapping Project: National Report 2018-19.

[9] ASHM. Viral Hepatitis Mapping Project: National Report 2018-19.

[10] Ibid.

[11] Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia: Annual surveillance report 2018.

[12] Ibid.

[13] ASHM. Viral Hepatitis Mapping Project: National Report 2018-19.

[14] ASHM. Viral Hepatitis Mapping Project: National Report 2017.

[15] ASHM. Viral Hepatitis Mapping Project: National Report 2018-19.

[16] Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia: Annual surveillance report 2018.

[17] Ibid.

[18] Ibid.

[19] Fifth National Aboriginal and Torres Strait Islander Blood Borne Viruses and Sexually Transmissible Infections Strategy 2018-2022.

[20] Ward, J. (2019, 6 August). Aboriginal and Torres Strait Islander Researcher & Community Perspective. Plenary presentation at the Australasian Viral Hepatitis Elimination Conference, Sydney, NSW.

[21] Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia: Annual surveillance report 2018.

[22] ASHM. Viral Hepatitis Mapping Project: National Report 2018-19.

[23] Ibid.


Page updated 24 July 2020

Published: 29th November, 2018

Updated: 24th July, 2020

Author: Kevin Marriott

Share this page
  • Email
  • Facebook
  • Twitter

Latest

  • Parliamentary Morning Tea: We can eliminate hepatitis C!

    Parliamentary Morning Tea: We can eliminate hepatitis C!

    The Parliamentary Friends Group for Action of Blood Borne Viruses Co-Chairs, Tim Wilson, MP and Senator Louise Pratt invite you to a Parliamentary Morning Tea on Thursday 12 November.

  • Renewed calls for Needle & Syringe Programs in prisons ahead of International Drug Users Day

    Renewed calls for Needle & Syringe Programs in prisons ahead of International Drug Users Day

    The Australian Injecting and Illicit Drug Users League (AIVL) and Hepatitis Australia are highlighting international calls for Needle and Syringe Programs (NSPs) in prisons, along with a greater focus on harm reduction initiatives, ahead of International Drug Users Day on 1 November.

  • Investment in hepatitis research needs to be accompanied by National Strategy implementation funding

    Investment in hepatitis research needs to be accompanied by National Strategy implementation funding

    6 October 2020 - Hepatitis Australia welcomes the Australian Government’s commitment to diverse hepatitis research, however we remain concerned that the 2019 Health Budget funding for hepatitis commitments is yet to hit the ground.

  • Investment in liver cancer medicines matched with prevention are changing Australian lives

    Investment in liver cancer medicines matched with prevention are changing Australian lives

    6 October 2020 - Hepatitis Australia welcomes the Australian Government’s significant investment of $230 million to expand the listing of Tecentriq® and Avastin® (atezolizumab and bevacizumab) on the Pharmaceutical Benefits Scheme (PBS).

Related

  • Hepatitis B Guide

    Hepatitis B Guide

    Testing, treatment and staying healthy. This guide is to help you understand the process from being tested for hepatitis B (often called hep B) to living well with chronic (life-long) hep B.

  • Hepatitis C Guides

    Hepatitis C Guides

    Testing and treating hepatitis C: Information for GPs and patients. Download these pdf resources specific to doctors and patients. Most patients with hep C can now be safely managed and cured in primary care.

  • Clinical guidelines

    Clinical guidelines

    Australian guidelines for the testing and treatment of hepatitis B and hepatitis C

  • Mental Health Worker Information

    Mental Health Worker Information

    Information to support people working in mental health services when discussing hepatitis C.

  • Contact tracing in regional and remote areas

    Contact tracing in regional and remote areas

    This video is designed for health workers, especially those working closely with regional and remote Aboriginal and Torres Strait Islander communities.

  • Taskforce on BBVs, Sexual Health and COVID-19

    Taskforce on BBVs, Sexual Health and COVID-19

    The BBV and sexual health sector taskforce discusses the scientific, clinical, BBV and sexual health service delivery and social implications of COVID-19, and provides consistent and evidence-based messaging to the health workforce, sector partners and community.

  • COVID-19

    COVID-19

    Information on the coronavirus COVID-19 for people affected by hepatitis B or hepatitis C.

  • Eliminating Hepatitis

    Eliminating Hepatitis

    Resources to assist with achieving international goals to eliminate Viral Hepatitis by 2030.

  • Other Languages

    Other Languages

    Hepatitis Australia resources translated into various languages

  • Education Tools

    Education Tools

    Useful tools and guides to support the provision of hepatitis education.

Most read

  • Coronavirus COVID-19 factsheet for people with hepatitis B and hepatitis C

    Coronavirus COVID-19 factsheet for people with hepatitis B and hepatitis C

    Hepatitis Australia has put together a brief factsheet with information about the coronavirus COVID-19 for people living with hepatitis B and hepatitis C.

  • COVID-19

    COVID-19

    Information on the coronavirus COVID-19 for people affected by hepatitis B or hepatitis C.

  • Hepatitis A

    Basic information about hepatitis A in Australia

  • A cure for hepatitis C

    A cure for hepatitis C

    Highly effective medicines are now available in Australia to cure hepatitis C

  • Hepatitis B and relationships

    Hepatitis B and relationships

    Although most people get hepatitis B at birth, it can be transmitted in other ways including sex. This article contains information about how it is spreads, and how you can keep your partner safe.

  • What is hepatitis C?

    What is hepatitis C?

    Basic information about hepatitis C and how it can effect you.

  • Hepatitis B treatment

    Hepatitis B treatment

    Who needs treatment for hepatitis B and what is involved.

  • Hepatitis B vaccination

    Hepatitis B vaccination

    Hepatitis B can be prevented with a safe and effective vaccine.

  • Accessibility

  • Changes to immigration health requirement a positive move for migrants with hepatitis B

    Changes to immigration health requirement a positive move for migrants with hepatitis B

    21 August 2019 - Changes to the immigration health requirement will have a significant and positive impact for people with hepatitis B seeking to migrate permanently to Australia.

Join our mailing list

Interests

Info

Hepatitis Australia is a registered charity. 
ABN: 38 442 686 487

© Copyright 2019 Hepatitis Australia.
All rights reserved.
View our copyright statement here

Helpful links

  • Contact us
  • Full sitemap
  • Accessibillity
  • Terms & conditions
  • Privacy policy
  • Login
  • Logout
  • Manager

Member sites

  • Australian Capital Territory
  • New South Wales
  • Northern Territory
  • South Australia
  • Victoria
  • Queensland
  • Western Australia
  • Tasmania 

Information provided on this website is for general information only and not intended as medical advice. Hepatitis Australia encourages all readers to seek independent medical advice before making any decisions based on the information provided on this website.

Hepatitis Australia is a partner organisation of healthdirect Australia.
healthdirect - trusted health advice

This website is certified by Health On the Net Foundation. Click to verify.
This site complies with the HONcode standard for trustworthy health information: verify here.
Search only trustworthy HONcode health websites: 

Images used on this site may include stock photos and the associated messaging may not represent the personal situation, views or beliefs of the people in the images.